INTERNATIONAL JOURNAL OF SCIENTIFIC DEVELOPMENT AND RESEARCH International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2455-2631 | Impact factor: 8.15 | ESTD Year: 2016
open access , Peer-reviewed, and Refereed Journals, Impact factor 8.15
Abstract: Brexpiprazole has US Food and Drug Administration approval on July 10,2015 monotherapy treatment of schizophrenia and adjunctive treatment to antidepressants for major depressive disorder. It is an Antipsychotic drug.Brexpiprazole is a serotonin-dopamine activity modulator that acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors at similar potencies and as an antagonist at5-HT2Aand noradrenaline alpha1B/2Creceptors.These all lead to a favorable antipsychotic profile in terms of improvement of cognitive performance and sleep patterns, as well as effects on affective states and potential to treat core symptoms in Schizophrenia and major depressive disorder, including cognitive deficits with a low risk of adverse effects .Schizophrenia is a serious mental illness that interferes with a person’s ability to think clearly, make decisions ,manage emotions and relate to others. It is a complex, long-term medical illness.
Keywords:
Keywords: brexpiprazole, schizophrenia, Major Depressive Disorder, atypical Antipsychotic.
Cite Article:
"A review on Efficasy and Safety of Brexpiprazole for Treatment of Schizophrenia", International Journal of Science & Engineering Development Research (www.ijsdr.org), ISSN:2455-2631, Vol.6, Issue 5, page no.109 - 116, May-2021, Available :http://www.ijsdr.org/papers/IJSDR2105020.pdf
Downloads:
000337366
Publication Details:
Published Paper ID: IJSDR2105020
Registration ID:193292
Published In: Volume 6 Issue 5, May-2021
DOI (Digital Object Identifier):
Page No: 109 - 116
Publisher: IJSDR | www.ijsdr.org
ISSN Number: 2455-2631
Facebook Twitter Instagram LinkedIn